Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Future research in ITP: an ICIS consensus 3rd Intercontinental-Cooperative-ITP-Study-Group Expert Meeting Zehnder, J. L., Semple, J. W., Imbach, P., Neufeld, E. J., Buchanan, G. R., Cines, D. B. SPRINGER. 2010: S19–S23

Abstract

While much has been learned about the basic immunology and clinical characteristics of immune thrombocytopenia, many important questions remain with regard to pathogenesis, disease progression, identification of novel therapeutic targets and approaches, and clinical trials that rationalize and optimize use of existing therapies. The answers to these questions are likely to impact our understanding of the pathogenesis and therapeutic targets of autoimmune disease in general.

View details for DOI 10.1007/s00277-010-0917-1

View details for Web of Science ID 000279682100005